Program
Pioglitazone
Also written as “pioglitazone”, “Pioglitazone 30 mg” and “Pioglitazone and azilsartan”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Alzheimer Disease · Fatty Liver · Peripheral Arterial Disease, led by 10 companies.
Drug pagePioglitazone: every studyMany companies study it; this page follows only the 52 they lead. All 336 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takedaits history only | 330 open or running | phase 4since Jun 27, 2007 | Sep 9, 2005 | none ahead |
| Boryung Pharmaceuticalits history only | 42 open or running | phase 3since May 9, 2021 | May 9, 2021 | none ahead |
| Merckits history only | 40 open or running | phase 3since Jul 22, 2008 | Aug 2, 2007 | none ahead |
| GlaxoSmithKlineits history only | 30 open or running | phase 4since Apr 2, 2009 | Dec 22, 2005 | none ahead |
| Hoffmann-La Rocheits history only | 20 open or running | phase 4since Oct 16, 2007 | Oct 16, 2007 | none ahead |
| Viatrisits history only | 20 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| Dr. Muhammad Abdulghani | 10 open or running | no phasesince Aug 16, 2016 | Aug 16, 2016 | none ahead |
| Getz Pharmaits history only | 10 open or running | phase 4since Jul 19, 2021 | Jul 19, 2021 | none ahead |
| Medtronicits history only | 10 open or running | early phase 1since Jul 21, 2008 | Jul 21, 2008 | none ahead |
| Strekinits history only | 10 open or running | phase 3since Nov 1, 2017 | Nov 1, 2017 | none ahead |
Also a collaborator on its studies: Parexel, Zinfandel Pharmaceuticals, Eli Lilly and Takeda Pharmaceuticals North America.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Dr. Muhammad Abdulghani only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 16, 2016First study: no phase study in Diabetes Mellitus, Type 2First studyNCT02887625 · 410 enrolled · Qatar
TargetBeta
“Peroxisome proliferator-activated receptor gamma agonist”ChEMBL 37, by rule
Other programs on PPARG
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| saroglitazarrule | Zydus Lifesciences | phase 4 | 19 |
| chiglitazarrule | Chipscreen Biosciences | phase 3 | 9 |
| lanifibranor | inventiva-pharma | phase 3 | 6 |
| T3D-959rule | t3d-therapeutics-inc | phase 3 | 3 |
Studies
The one study Dr. Muhammad Abdulghani leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02887625Diabetes Mellitus, Type 2 · Qatar | – | UNKNOWN | May 2017 | 410 |
How it is read
Names in the registry
- “Pioglitazone”, 33 entries
- “pioglitazone”, 5 entries
- “Pioglitazone 30 mg”, 4 entries
- “Pioglitazone and azilsartan”, 4 entries
- “TAK-379”, 3 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 42 studies
- Diabetes Mellitus, 4 studies
- Alzheimer Disease, 2 studies
- Fatty Liver, 1 study
- Peripheral Arterial Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.